BR112021017436A2 - Composições farmacêuticas para tratamento de doenças ou transtornos oculares - Google Patents

Composições farmacêuticas para tratamento de doenças ou transtornos oculares

Info

Publication number
BR112021017436A2
BR112021017436A2 BR112021017436A BR112021017436A BR112021017436A2 BR 112021017436 A2 BR112021017436 A2 BR 112021017436A2 BR 112021017436 A BR112021017436 A BR 112021017436A BR 112021017436 A BR112021017436 A BR 112021017436A BR 112021017436 A2 BR112021017436 A2 BR 112021017436A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
disorders
ocular diseases
treating ocular
released
Prior art date
Application number
BR112021017436A
Other languages
English (en)
Inventor
Cheng-Wen Lin
Kumar Das Sanjib
Original Assignee
Aerie Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aerie Pharmaceuticals Inc filed Critical Aerie Pharmaceuticals Inc
Publication of BR112021017436A2 publication Critical patent/BR112021017436A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

composições farmacêuticas para tratamento de doenças ou transtornos oculares. nesta divulgação são fornecidas composições farmacêuticas, implantes intravítreos e suspensões de partículas compreendendo uma matriz de polímero e, pelo menos, um agente terapêutico que é liberado de uma maneira substancialmente linear por um período particular.
BR112021017436A 2019-03-05 2020-03-05 Composições farmacêuticas para tratamento de doenças ou transtornos oculares BR112021017436A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962814198P 2019-03-05 2019-03-05
PCT/US2020/021136 WO2020181060A1 (en) 2019-03-05 2020-03-05 Pharmaceutical compositions for treating ocular diseases or disorders

Publications (1)

Publication Number Publication Date
BR112021017436A2 true BR112021017436A2 (pt) 2021-11-16

Family

ID=72337143

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021017436A BR112021017436A2 (pt) 2019-03-05 2020-03-05 Composições farmacêuticas para tratamento de doenças ou transtornos oculares

Country Status (10)

Country Link
US (1) US20200306182A1 (pt)
EP (1) EP3934646A4 (pt)
JP (1) JP2022523548A (pt)
KR (1) KR20210135560A (pt)
CN (1) CN113784727B (pt)
AU (1) AU2020232314C1 (pt)
BR (1) BR112021017436A2 (pt)
CA (1) CA3132635A1 (pt)
MX (1) MX2021010599A (pt)
WO (1) WO2020181060A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2952213T3 (es) 2020-02-06 2023-10-30 Ocular Therapeutix Inc Composiciones y métodos para tratar enfermedades oculares
BR112022018815A2 (pt) 2020-03-25 2022-11-29 Ocular Therapeutix Inc Implante ocular contendo um inibidor de tirosina cinase
WO2022232588A1 (en) 2021-04-30 2022-11-03 Perfuse Therapeutics, Inc. Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases
WO2022235906A1 (en) 2021-05-05 2022-11-10 Aerie Pharmaceuticals, Inc. Pharmaceutical preparation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2019645A4 (en) * 2006-05-02 2013-03-06 Medivas Llc RELEASE OF OPHTHALMOLOGICAL ACTIVITIES OUTSIDE OR WITHIN THE EYE
CN102014879A (zh) * 2008-04-25 2011-04-13 帝斯曼知识产权资产管理有限公司 含有具有硫酯键的聚合物的颗粒
KR101699497B1 (ko) * 2010-06-22 2017-01-24 도요보 가부시키가이샤 액정표시장치, 편광판 및 편광자 보호 필름
WO2012150255A1 (en) * 2011-05-02 2012-11-08 Dsm Ip Assets B.V. Bis-(alpha-amino-diol-diester) containing polyesteramide for ophtamology
US20140179802A1 (en) * 2011-05-02 2014-06-26 Dsm Ip Assets B.V. Fiber comprising a biodegradable polymer
US9789189B2 (en) * 2012-10-02 2017-10-17 Dsm Ip Assets Bv Drug delivery composition comprising proteins and biodegradable polyesteramides
RU2015146211A (ru) * 2013-04-01 2017-05-19 Аллерган, Инк. Микросферная система доставки лекарственного средства для замедленного внутриглазного высвобождения
CN105431135A (zh) * 2013-11-08 2016-03-23 泰尔克斯公司 用于治疗手术并发症的聚合给药系统
US20160296627A1 (en) * 2013-12-06 2016-10-13 Envisia Therapeutics Inc. Intracameral implant for treatment of an ocular condition
EP3082761A2 (en) * 2013-12-20 2016-10-26 Emory University Formulations and methods for targeted ocular delivery of therapeutic agents
JP7026507B2 (ja) * 2014-09-06 2022-02-28 インテグラル バイオシステムズ エルエルシー 眼において薬物徐放を達成する方法及び生体適合性組成物
WO2016097297A1 (en) * 2014-12-18 2016-06-23 Dsm Ip Assets B.V. Drug delivery system for delivery of acid sensitive drugs
EP3324944A4 (en) * 2015-07-23 2019-04-03 Aerie Pharmaceuticals, Inc. INTRAVITREAL AGGREGATION SYSTEMS FOR THE TREATMENT OF EYE DISEASE
WO2017120600A1 (en) * 2016-01-08 2017-07-13 Clearside Biomedical, Inc. Compositions and methods of treating wet age-related macular degeneration
US20180117148A1 (en) * 2016-10-28 2018-05-03 Andrew J. Holman Compounds, pharmaceutical compositions and methods of treatments of immune related diseases and disorders
EP3570888A1 (en) * 2017-03-03 2019-11-27 MacRegen, Inc. Treatment of age-related macular degeneration and other eye diseases with one or more therapeutic agents

Also Published As

Publication number Publication date
EP3934646A4 (en) 2022-12-14
WO2020181060A1 (en) 2020-09-10
AU2020232314A1 (en) 2021-09-30
AU2020232314B2 (en) 2023-10-12
AU2020232314C1 (en) 2024-03-28
US20200306182A1 (en) 2020-10-01
MX2021010599A (es) 2021-12-10
CA3132635A1 (en) 2020-09-10
CN113784727A (zh) 2021-12-10
KR20210135560A (ko) 2021-11-15
JP2022523548A (ja) 2022-04-25
CN113784727B (zh) 2024-03-29
EP3934646A1 (en) 2022-01-12

Similar Documents

Publication Publication Date Title
BR112021017436A2 (pt) Composições farmacêuticas para tratamento de doenças ou transtornos oculares
BR112018068906A2 (pt) composição, método, método de redução de risco, prevenção ou tratamento de um indivíduo que tem uma doença ou distúrbio autoimune, método de indução de degradação de uma proteína-alvo numa célula, método para reduzir o risco, prevenir ou tratar um estado da doença ou afecção num paciente em que a atividade proteica desregulada é responsável pelo referido estado da doença ou afecção, método para reduzir o risco, prevenir ou tratar câncer num indivíduo e método de tratamento de uma doença ou distúrbio genético num indivíduo
BR112018010018A2 (pt) moduladores de ror-gama
BR112018017172A2 (pt) anticorpos monoclonais anti-alfa-sinucleína para prevenção da agregação de tau
BR112017017448A2 (pt) métodos e composições para o tratamento de doença do olho ressecado e outros distúrbios do olho
BR112017015059A2 (pt) inibidor de proteassoma e uso
BR112016025312A2 (pt) variantes de anticorpo, anticorpo anti-fator d, formulação farmacêutica, dispositivo de distribuição, utilização da formulação e de uma composição, composição e método de tratamento de uma desordem
MX2017016134A (es) Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad.
MX2022001874A (es) Receptores agonistas no peptidicos de somatostatina tipo 5 y usos de los mismos.
UY38160A (es) Partículas implantables y métodos relacionados
DOP2007000015A (es) Usos terapéuticos de inhibidores de rtp801
BR112018072545A2 (pt) inibidores da arginase e suas aplicações terapêuticas
BR112017020948A2 (pt) composição farmacêutica, método para preparar um agente, método para tratar uma doença ocular e uso de uma proteína de fusão
BR112021019070A2 (pt) Ligantes de pseudoquinase tyk2
CO2019002245A2 (es) Combinación de agonistas de fxr
BR112021015751A2 (pt) Vetores de terapia genética para tratamento da doença de danon
MX2022009762A (es) Moduladores del purinorreceptor 3 p2x (p2x3).
CL2022001178A1 (es) Ligandos de la pseudoquinasa tyk2
BR112019003912A2 (pt) composição, método para criação de um hidrogel, matriz, hidrogel, método para indução da formação ou regeneração de um tecido neuronal, método para tratamento de uma lesão do nervo e método para prevenção ou tratamento de choque neurogênico após lesão do nervo
BR112021017820A2 (pt) Composições e métodos para modulação da atividade de complemento
BR112022009710A2 (pt) Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2
CO2022014499A2 (es) Moduladores de nlrp3
BR112017008805A2 (pt) tratamento de córnea usando laminina
CL2018000430A1 (es) Compuesto de hidroxitriazina y uso médico relacionado.
MX2023003675A (es) Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos.